Lewetiracetam i markery stresu oksydacyjnego w epilepsji: przegląd systematyczny doniesień u ludzi

PubMed➕ 26.09.2026Int J Mol Sci

Levetiracetam and Peripheral Oxidative Stress Biomarkers in Epilepsy: A Systematic Review of Human Evidence

W skrócie

Naukowcy przeanalizowali dostępne badania, aby sprawdzić, czy lek na epilepsję zwany lewetiracetamem wpływa na procesy chemiczne w organizmie związane ze stresem oksydacyjnym. Okazało się, że istniejące badania są zbyt różne i niedokładne, aby wyciągnąć pewne wnioski na temat tego wpływu. Autorzy wskazują, że przed powiedzeniem czegokolwiek na pewno potrzebne są lepsze, bardziej spójne badania naukowe.

Oryginalny abstract (angielski)

Oxidative stress is implicated in epilepsy, but seizures, disease severity, diet, comorbidity and treatment all influence circulating redox biomarkers. We systematically reviewed human evidence on levetiracetam (LEV) under three estimands: within-person change, LEV-treated epilepsy versus healthy controls, and LEV versus other antiseizure medications. PubMed/MEDLINE, Cochrane Library, Web of Science and Scopus were searched from inception to 15 July 2026 (PROSPERO CRD420261448016; OSF HXA4U). Eleven non-randomized studies contributed 297 participants-the sum of LEV subgroups with analysable biomarker data, not the total enrolled populations. Effect estimates with 95% confidence intervals were calculated here wherever reporting permitted; none could be derived for four studies, and those derived are wide, inconsistent in direction, or from designs that cannot attribute change to LEV. Meta-analysis was inappropriate: definitions, matrices, assays, estimands and variance reporting were incompatible. Certainty was very low for every outcome-domain/comparator body, and a sensitivity analysis excluding one report failing a post hoc source-verifiability check (10 studies, 265 participants) changed no conclusion. This review's contribution is not an estimate of LEV's redox effect but a demonstration of why the literature cannot establish one: the human evidence is not of sufficient validity to support or refute such an effect.

Metadane publikacji

Journal
Int J Mol Sci
Data publikacji
21.09.2026
PMID
42794835
DOI
10.3390/ijms27188410
Autorzy
Mîndreanu R, Clichici S, Buleteanu B, Badea M, Pop M, Cherecheș RM, Login C
Słowa kluczowe
SWiM, biomarkers, epilepsy, evidence gap, glutathione, levetiracetam, lipid peroxidation, oxidative stress
Źródło
PubMed